Tumor relapse after
human leukocyte antigen-matched allogeneic
stem cell transplantation (SCT) remains a serious problem, despite the long-term presence of
minor histocompatibility antigen (
MiHA)-specific memory T cells. Dendritic cell (DC)-based vaccination boosting
MiHA-specific T-cell immunity is an appealing strategy to prevent or counteract
tumor recurrence, but improvement is necessary to increase the clinical benefit. Here, we investigated whether knockdown of
programmed death ligand 1 (PD-L1) and PD-L2 on monocyte-derived DCs results in improved T-cell activation. Electroporation of single
siRNA sequences into immature DCs resulted in efficient, specific, and long-lasting knockdown of PD-L1 and PD-L2 expression. PD-L knockdown DCs strongly augmented
interferon-γ and
interleukin-2 production by stimulated T cells in an allogeneic mixed lymphocyte reaction, whereas no effect was observed on T-cell proliferation. Moreover, we demonstrated that PD-L gene silencing, especially combined PD-L1 and PD-L2 knockdown, resulted in improved proliferation and
cytokine production of
keyhole limpet hemocyanin-specific CD4(+) T cells. Most importantly, PD-L knockdown DCs showed superior potential to expand
MiHA-specific CD8(+) effector and memory T cells from
leukemia patients early after donor lymphocyte infusion and later during relapse. These data demonstrate that PD-L
siRNA electroporated DCs are highly effective in enhancing T-cell proliferation and
cytokine production, and are therefore attractive cells for improving the efficacy of DC
vaccines in
cancer patients.